
    
      Following Run-In, patients qualifying for treatment were randomized 2:1 to receive ESBA105
      (experimental group) or Vehicle (control group) for 4 weeks. Patients not qualifying for
      treatment (based on global VAS discomfort score), were discontinued from the study.
    
  